PreveCeutical Files an Application for a Provisional Patent for Sol-gel Cannabinoids
Vancouver, British Columbia--(Newsfile Corp. - August 31, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on August 31, 2020, entitled "Cannabinoid Formulations and Methods of Use", application number 2020903103, in order to protect sol-gel formulations containing cannabinoids for nasal delivery. The patent also covers cannabinoid...
2020-08-31 7:00 AM EDT
PreveCeutical Receives AU$1,227,902 Research & Development Tax Incentive Cash Refund
Vancouver, British Columbia--(Newsfile Corp. - August 17, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has received AU$1,227,902 cash rebate from the Australian Federal Government's Research and Development ("R&D") Incentive Program. The cash refund is related to expenditure on eligible Australian R&D activities conducted during the financial year ended December 31, 2019. The R&D activities were...
2020-08-17 7:00 AM EDT
PreveCeutical Announces Appointment of Director and Public Officer
Vancouver, British Columbia--(Newsfile Corp. - July 30, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the appointment of Edward James Henderson as the Public Officer and Director of its subsidiary company, PreveCeutical (Australia) Pty Ltd. (the "Subsidiary") effective immediately. Mr. Henderson is HLB Mann Judd's Managing Partner, Business Advisory Services, Tax Consulting, Brisbane, Queensland, Australia....
2020-07-30 7:00 AM EDT
PreveCeutical Approaches Completion of Non-Addictive Analgesic Program
Vancouver, British Columbia--(Newsfile Corp. - July 21, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that the current stage of the research of its disulfide linker technology in engineering analgesic peptides derived from endogenous pharmacology program ("Analgesic Program") is soon to complete. The results are currently being compiled and analyzed. The Analgesic Program started in July 2018 to expand the...
2020-07-21 7:00 AM EDT
PreveCeutical Announces Advance in the Formulation and Biological Delivery of Therapy for Diabetes and Obesity
Vancouver, British Columbia--(Newsfile Corp. - July 15, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it has successfully demonstrated that delivery efficiency can be tailored based on vector composition in its Dual Gene Therapy Research Program. This update of PreveCeutical's Dual Gene Therapy Program, (see earlier release on January 14, 2020, and June 29, 2020), has identified a promising modified delivery vector...
2020-07-15 7:00 AM EDT
PreveCeutical Confirms Receipt of CBD For Sol-Gel
Vancouver, British Columbia--(Newsfile Corp. - July 13, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") is pleased to inform that the cannabis product required for its cannabinoid Sol-Gel program to address the COVID-19 pandemic (the "COVID-19 Sol-gel") (News Release dated May 4, 2020), was received by Pharmacy Australia Centre of Excellence ("PACE"), University of Queensland ("UQ") on July 8, 2020. PreveCeutical can now commence with the COVID-19...
2020-07-13 7:00 AM EDT
PreveCeutical Announces Filing of Provisional Patent Application
Vancouver, British Columbia--(Newsfile Corp. - July 8, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on July 1, 2020, entitled "Peptides and Uses Thereof", application number 2020902233, with the aim of seeking protection for certain peptides analogues of dynorphin and their use in pain management. PreveCeutical's Chief Executive Officer,...
2020-07-08 7:00 AM EDT
PreveCeutical Announces Stability Data from CBD Sol-gel Product Development Program
Vancouver, British Columbia--(Newsfile Corp. - July 6, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce successful results from its Cannabinoid sol-gel product development program. We have successfully conducted a three-month physico-chemical stability test on cannabinoid sol-gel formulations designed for nose-to-brain ("NTB") delivery. The physical and chemical stability of formulated cannabinoid components was characterized...
2020-07-06 7:00 AM EDT
PreveCeutical Announces Promising 3D Liver Tissue Testing of Potential Therapy for Diabetes and Obesity
Vancouver, British Columbia--(Newsfile Corp. - June 29, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it has successfully designed, screened and shortlisted a panel of smart-siRNA constructs with potent gene silencing activity (in vitro) in its Dual Gene Therapy Research Program. This further update to the Company's Dual Gene Therapy Program, (see earlier release on January 14, 2020), is an important and fundamental...
2020-06-29 7:00 AM EDT
PreveCeutical Executes Agreement for Development of CBD Sol-Gel Nasal Spray Formulation as a Potential Treatment for SARS-CoV-2 Infection
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that on June 18th, 2020, it has contracted UniQuest Pty Ltd. ("UniQuest") to apply the cannabinoid sol-gel ("CBD Sol-Gel") technology to develop a nasal spray formulation as a potential treatment for COVID-19 caused by SARS-CoV-2 infection. The Company is not making any express or implied claims that its product has the...
2020-06-22 12:23 PM EDT
PreveCeutical Announces Sol-Gel Chemistry Fingerprinting SOPs
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it has successfully developed 'Standard Operating Procedures' ("SOPs") allowing for the chemical fingerprinting (profiling) of cannabinoids present in its extracts which can be used to formulate its proprietary Sol-gels for a variety of potential therapeutic applications. This is an important development enabling a...
2020-06-17 7:00 AM EDT
PreveCeutical Issued Statement Regarding Promotional Activity
Vancouver, British Columbia--(Newsfile Corp. - June 16, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") provides the following information about certain promotional activities at the request of OTC Markets. On June 15, 2020, the Company was notified by OTC Markets that recently, certain materials promoting PreveCeutical's common stock were circulated via email by a third party. Copies of the promotional emails were forwarded to PreveCeutical's CFO by...
2020-06-16 7:13 PM EDT
PreveCeutical Announces Further Successful Results from The Sol-Gel Program Final Report
Vancouver, British Columbia--(Newsfile Corp. - June 15, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical") is pleased to announce the successful completion of its cannabinoid sol-gel program (the "Sol-gel Program") with the University of Queensland ("UQ") and UniQuest Pty Ltd. ("UniQuest). The final report confirms the successful chemical profiling of the solvent-derived cannabinoid extracts from cannabis plant species, which has provided the Company...
2020-06-15 7:00 AM EDT
PreveCeutical Announces Certain Warrants Expiring on June 29, 2020
Vancouver, British Columbia--(Newsfile Corp. - June 8, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is informing its shareholders that 134,151,350 common share purchase warrants (the "Warrants") issued in connection with the Company's June 29, 2018, non-brokered private placement, including 6,301,600 finder's warrants, will expire on June 29, 2020. Each Warrant currently entitles the holder thereof to purchase one common share of...
2020-06-08 7:00 AM EDT
PreveCeutical Announces Successful Completion of its Sol-gel Program
Vancouver, British Columbia--(Newsfile Corp. - June 3, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the successful completion of its Cannabinoid Sol-Gel Delivery Program (the "Sol-gel Program"). The Sol-gel Program developed and evaluated translatable formulations for the central nervous system (CNS) delivery of cannabinoid extracts ("CBDs"). Soluble gels (solgels) present an ideal platform for achieving...
2020-06-03 7:00 AM EDT
PreveCeutical Applies for Viral Prevention Program Funding
Vancouver, British Columbia--(Newsfile Corp. - June 1, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), is pleased to inform that, in connection with its previously announced extension to its successful cannabis sol-gel program (the "Program Extension") to address the COVID-19 pandemic (News Release dated May 4, 2020), PreveCeutical was identified as a candidate to submit a preliminary application to the Strategic Innovation Fund...
2020-06-01 8:52 AM EDT
PreveCeutical Announces Debt Settlement and Conversion of Debt
Vancouver, British Columbia--(Newsfile Corp. - May 22, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that it has issued 95,600,253 common shares without par value in its capital (each, a "Share") to various arm's length creditors of the Company at a deemed issuance price of $0.023 per Share. The Company has entered into a shares for debt settlement agreement with an arm's length supplier (the "Supplier"), whereby the...
2020-05-22 5:02 PM EDT
PreveCeutical Announces Possible Viral Prevention Program Using CBD Sol-gel
Vancouver, British Columbia--(Newsfile Corp. - May 4, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), is pleased to announce that it is working on an extension to its successful cannabis sol-gel program to address the COVID-19 pandemic (the "Program Extension"). The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time. The focus of the...
2020-05-04 1:37 PM EDT
PreveCeutical Confirms its First Peptide with Promising Pre-Clinical Efficacy as a Non-Addictive Painkiller
Vancouver, British Columbia--(Newsfile Corp. - April 29, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce an update to its Non-Addictive Analgesic (dynorphin pain peptide) Program. Following the identification and shortlisting of a panel of peptides showing promising cell-based activity and extended stability in two distinct types of biological media, the program has identified its first peptide with clear "in...
2020-04-29 8:00 AM EDT
PreveCeutical Announces Patent Cooperation Treaty ("PCT") Application
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that the two Australian provisional applications entitled, "A Cyclic Peptide", which were filed last year by The University of Queensland, Australia ("UQ") have recently been combined into a single PCT application which was filed a year after the earlier priority date. This PCT application, jointly owned...
2020-02-24 8:00 AM EST